$SRPT Cashflow Statement | Understand Stock

$SRPT

$18.89 +$0.91 (5.06%) Close

$SRPT Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net (loss) income
Adjustments to reconcile net (loss) income to net cash flow from operating activities
Non-cash inventory write-downs for excess and obsolescence
Stock-based compensation
Loss on disposal of assets
In-kind milestone payment to Arrowhead Pharmaceuticals
Depreciation and amortization
Loss on investment in Arrowhead Pharmaceuticals
Non-cash write-off of prepaid deposits
(Gain) loss on debt extinguishment
Reduction in the carry amounts of the right of use assets
Non-cash interest expense
Accretion of investment discount, net
Non-cash termination charges
Change in the fair value of derivatives
Impairment of strategic investments
Gain from sale of Priority Review Voucher
Other

Changes in operating assets and liabilities, net:
Decrease (increase) in accounts receivable
Increase in inventory
Decrease (increase) in manufacturing-related deposits and prepaids
(Increase) decrease in other assets
Increase (decrease) in deferred revenue
Increase (decrease) in accounts payable, accrued expenses, lease liabilities and other liabilities
Net cash used in operating activities
Cash flows from investing activities:
Maturity and sale of available-for-sale securities
Acquisition of strategic investments
Other
Proceeds from sale of investment in Arrowhead Pharmaceuticals
Purchase of property and equipment
Purchase of available-for-sale securities
Purchase of intangible assets and other
Proceeds from sale of Priority Review Voucher
Net cash provided by (used in) investing activities

Cash flows from financing activities:
Repayment of 2027 Notes, including debt extinguishment costs
Repurchases of common stock, net of excise tax
Proceeds from issuance of common stock
Debt issuance costs for the August 2025 Exchange and December 2025 Exchange (defined in Note 13)
Proceeds from exercise of stock options and purchase of stock under the Employee Stock Purchase Program
Payments related to Revolving Credit Facility
Common stock issuance costs
Settlement of capped call share options for 2024 Notes
Payment on maturity of 2024 Notes
Proceeds from 2027 Notes offering, net of commissions
Purchase of capped call share options for 2027 Notes
Repurchase of 2024 Notes
Repayment of principal amount due under 2019 Term Loan
Payment on debt extinguishment of 2019 Term Loan
Taxes paid related to net share settlement of equity awards
Proceeds from sales of common stock, net of offering costs
Proceeds from 2019 Term Loan
Debt issuance costs for 2019 Term Loan
Net cash (used in) provided by financing activities

(Decrease) increase in cash and cash equivalents
Cash, cash equivalents and restricted cash:
Beginning of year
End of year
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents
Restricted cash in other assets
Total cash, cash equivalents and restricted cash
Supplemental disclosure of cash flow information:
Cash paid during the year for interest
Cash paid during the year for income taxes
Supplemental schedule of non-cash activities:
Non-cash settlement of 2027 Notes in Exchange Transactions (defined in Note 13)
Issuance of 2030 Notes in exchange for 2027 Notes
Common stock issued for conversion or exchange of 2027 Notes
Incremental option value associated with the December 2025 Exchange (defined in Note 13)
Contingent consideration liabilities derecognized in connection with adoption of ASU 2025-07 (see Note 2)
Capitalized stock-based compensation and depreciation as inventory
Reduction in lease liability embedded in CMO agreement due to remeasurement
Lease liabilities arising from obtaining right of use assets
Intangible assets and property and equipment included in accounts payable and accrued expenses
Accrued debt issuance costs for the Exchange Transactions
Common stock issued for conversion or exchange of 2024 Notes
Lease liabilities terminated
Accrued debt issuance costs
Shares withheld for tax included in accrued expenses

Comments